352 related articles for article (PubMed ID: 34043900)
1. Cannabis and cannabinoid use in autism spectrum disorder: a systematic review.
Silva EAD; Medeiros WMB; Torro N; Sousa JMM; Almeida IBCM; Costa FBD; Pontes KM; Nunes ELG; Rosa MDD; Albuquerque KLGD
Trends Psychiatry Psychother; 2022 Jun; 44():e20200149. PubMed ID: 34043900
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid treatment for the symptoms of autism spectrum disorder.
Aran A; Cayam Rand D
Expert Opin Emerg Drugs; 2024 Mar; 29(1):65-79. PubMed ID: 38226593
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol as a suggested candidate for treatment of autism spectrum disorder.
Poleg S; Golubchik P; Offen D; Weizman A
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():90-96. PubMed ID: 30171992
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial.
Silva EAD; Medeiros WMB; Santos JPMD; Sousa JMM; Costa FBD; Pontes KM; Borges TC; Espínola C; Andrade E Silva AH; Nunes ELG; Alves NT; Rosa MDD; Albuquerque KLGD
Trends Psychiatry Psychother; 2024; 46():e20210396. PubMed ID: 35617670
[TBL] [Abstract][Full Text] [Related]
5. Current state of evidence of cannabis utilization for treatment of autism spectrum disorders.
Agarwal R; Burke SL; Maddux M
BMC Psychiatry; 2019 Oct; 19(1):328. PubMed ID: 31664964
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid treatment for autism: a proof-of-concept randomized trial.
Aran A; Harel M; Cassuto H; Polyansky L; Schnapp A; Wattad N; Shmueli D; Golan D; Castellanos FX
Mol Autism; 2021 Feb; 12(1):6. PubMed ID: 33536055
[TBL] [Abstract][Full Text] [Related]
7. Systematic review and guide to management of core and psychiatric symptoms in youth with autism.
Ameis SH; Kassee C; Corbett-Dick P; Cole L; Dadhwal S; Lai MC; Veenstra-VanderWeele J; Correll CU
Acta Psychiatr Scand; 2018 Nov; 138(5):379-400. PubMed ID: 29904907
[TBL] [Abstract][Full Text] [Related]
8. A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms.
Werneck MA; Kortas GT; de Andrade AG; Castaldelli-Maia JM
CNS Drugs; 2018 Dec; 32(12):1113-1129. PubMed ID: 30361897
[TBL] [Abstract][Full Text] [Related]
9. Impact of polyunsaturated fatty acids on patient-important outcomes in children and adolescents with autism spectrum disorder: a systematic review.
De Crescenzo F; D'Alò GL; Morgano GP; Minozzi S; Mitrova Z; Saulle R; Cruciani F; Fulceri F; Davoli M; Scattoni ML; Nardocci F; Schünemann HJ; Amato L;
Health Qual Life Outcomes; 2020 Feb; 18(1):28. PubMed ID: 32066439
[TBL] [Abstract][Full Text] [Related]
10. Implications of the endocannabinoid system and the therapeutic action of cannabinoids in autism spectrum disorder: A literature review.
de Camargo RW; de Novais Júnior LR; da Silva LM; Meneguzzo V; Daros GC; da Silva MG; de Bitencourt RM
Pharmacol Biochem Behav; 2022 Nov; 221():173492. PubMed ID: 36379443
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications.
Holdman R; Vigil D; Robinson K; Shah P; Contreras AE
Cannabis Cannabinoid Res; 2022 Aug; 7(4):451-463. PubMed ID: 34432543
[No Abstract] [Full Text] [Related]
12. Repetitive and restricted behaviours and anxiety in autism spectrum disorder: protocol for a systematic review and meta-analysis.
Sellick T; Ure A; Williams K
Syst Rev; 2021 Dec; 10(1):303. PubMed ID: 34857047
[TBL] [Abstract][Full Text] [Related]
13. The effectiveness and adverse effects of D-cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder.
Aye SZ; Ni H; Sein HH; Mon ST; Zheng Q; Wong YKY
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013457. PubMed ID: 33583058
[TBL] [Abstract][Full Text] [Related]
14. Canadian clinical practice guidelines for the use of plant-based cannabis and cannabinoid-based products in the management of chronic non-cancer pain and co-occurring conditions: protocol for a systematic literature review.
Wright P; Walsh Z; Margolese S; Sanchez T; Arlt S; Belle-Isle L; St Pierre M; Bell A; Daeninck P; Gagnon M; Lacasse G; MacCallum C; Mandarino E; Yale J; O'Hara J; Costiniuk C
BMJ Open; 2020 May; 10(5):e036114. PubMed ID: 32448797
[TBL] [Abstract][Full Text] [Related]
15. Oxytocin Effect in Adult Patients with Autism: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Kiani Z; Farkhondeh T; Aramjoo H; Aschner M; Beydokhti H; Esmaeili A; Arab-Zozani M; Samarghandian S
CNS Neurol Disord Drug Targets; 2023; 22(6):906-915. PubMed ID: 35585805
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole for treating irritability associated with autism spectrum disorders.
Bartram LA; Lozano J; Coury DL
Expert Opin Pharmacother; 2019 Aug; 20(12):1421-1427. PubMed ID: 31180743
[No Abstract] [Full Text] [Related]
17. Autism Spectrum Disorder: A Review.
Hirota T; King BH
JAMA; 2023 Jan; 329(2):157-168. PubMed ID: 36625807
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
Pedrazzi JFC; Ferreira FR; Silva-Amaral D; Lima DA; Hallak JEC; Zuardi AW; Del-Bel EA; Guimarães FS; Costa KCM; Campos AC; Crippa ACS; Crippa JAS
Psychopharmacology (Berl); 2022 Sep; 239(9):2713-2734. PubMed ID: 35904579
[TBL] [Abstract][Full Text] [Related]
19. Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder.
Poleg S; Kourieh E; Ruban A; Shapira G; Shomron N; Barak B; Offen D
Transl Psychiatry; 2021 Oct; 11(1):524. PubMed ID: 34645786
[TBL] [Abstract][Full Text] [Related]
20. Autism Spectrum Disorder and Medical Cannabis: Review and Clinical Experience.
Mostafavi M; Gaitanis J
Semin Pediatr Neurol; 2020 Oct; 35():100833. PubMed ID: 32892960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
